ObsEva SA/ CH1260041939 /
08/03/2024 17:02:03 | Chg. - | Volume | Bid10:04:48 | Ask17:19:05 | High | Low |
---|---|---|---|---|---|---|
0.018CHF | - | 1,869 Turnover: 40.466 |
-Bid Size: - | -Ask Size: - | 0.025 | 0.018 |
GlobeNewswire
03/04
ObsEva Announces Delisting from SIX Swiss Exchange and Exemption from Certain Obligations Associated...
GlobeNewswire
08/03
XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming ...
GlobeNewswire
28/02
ObsEva Announces Wind-Down of Operations and Notifies SIX that it Will Lack the Resources to Establi...
GlobeNewswire
07/11/2023
XOMA Reports Third Quarter 2023 Financial Results and Highlights Upcoming Events Expected to Drive S...
GlobeNewswire
22/03/2022
ObsEva Announces Additional Efficacy Results for Linzagolix 200 mg with Add-Back Therapy (ABT) and L...
GlobeNewswire
22/03/2022
ObsEva Announces Additional Efficacy Results for Linzagolix 200 mg with Add-Back Therapy (ABT) and L...
GlobeNewswire
10/03/2022
ObsEva Announces Year End 2021 Financial Results and Provides Corporate Update
GlobeNewswire
10/02/2022
ObsEva Enters into Licensing Agreement with Theramex for the Commercialization of Linzagolix
GlobeNewswire
04/02/2022
ObsEva Provides Update on EU Marketing Authorisation Process for Linzagolix, an Oral GnRH Antagonist...
GlobeNewswire
06/01/2022
ObsEva Announces Positive Topline Results for Linzagolix 200 mg with Add-Back Therapy in the Phase 3...
GlobeNewswire
05/01/2022
Aspira Women’s Health Announces Fourth Quarter Operational Metrics and Provides Updates on Its OvaWa...
GlobeNewswire
17/12/2021
ObsEva Announces Positive CHMP Opinion for Linzagolix, an Oral GnRH Antagonist, for the Treatment of...
GlobeNewswire
10/12/2021
ObsEva Hosts Symposium and Presents Clinical Data on Oral GnRH Antagonist Linzagolix at SEUD Congres...